Use Of Preferred Providers Among Small Molecule Outsourcers

In Q32021, ISR surveyed outsourcers of small molecule API and outsourcers of small molecule drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing. The data show use of preferred providers is slightly more common for small molecule API than small molecule drug product manufacturing (56% vs. 51%). To learn more, follow the links to the Small Molecule API and the Small Molecule Drug Product report previews.